J. T. Huse

This study shows that ATRX loss primes glioma cells for innate immune recognition, while IDH1R132H mutation suppresses immune signaling, which can be reversed by IDH1 inhibition.

This study shows TREM2 promotes phagocytosis in gliomas and is not linked to immunosuppression, suggesting TREM2 activation could enhance immunotherapy for brain tumors.

This study shows that SIRT2 inhibition induces senescence in ATRX-deficient glioma models by altering chromatin landscapes and transcriptional profiles.

This study shows that hepaCAM suppresses GBM stem cell invasion by balancing ECM adhesion and signaling pathways, suggesting it as a potential therapeutic target.

This study analyzes longitudinal glioma data to identify recurrence-associated changes in genetics and microenvironment linked to therapy resistance.

This paper demonstrates that 1H-13C HSQC NMR can detect oncometabolic aberrations in live cells and tumors without specialized equipment, improving sensitivity and resolution over traditional methods.

This paper shows that MTA levels are not significantly elevated in MTAP-homozygous deleted primary human glioblastomas, challenging the clinical relevance of targeting PRMT5 and MAT2A in these tumors.

This study shows ATRX deficiency in glioma causes genomic instability via G-quadruplex DNA, and G4 stabilization can be therapeutically targeted.